(P085) Exploiting Androgen-Induced DNA Double-Strand Breaks: Optimal Sequencing of Androgen Suppression and Radiation for Superior Tumor Control in the Treatment of Prostate Cancer

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

We provide evidence that irradiating tumors at a time point when formation of androgen-induced double-strand breaks is ongoing provides superior control when compared with radiation that is delivered when tumors are fully deprived of androgens. These results may have significant implications for altering current clinical management of intermediate-and high-risk prostate cancer treated with definitive radiotherapy.

Raju R. Raval, MD, DPhil, Mohammad Hedayati, PhD, Michael C. Haffner, MD, Yonggang Zhang, MD, Haoming Zhou, BS, Emma J. Knight, BS, Michele E. Wabler, MS, Susan Dalrymple, BS, John T. Isaacs, PhD, Aileen Santos, BS, Russell Hales, MD, Srinivasan Yegnasubramanian, MD, PhD, Theodore L. DeWeese, MD; Department of Radiation Oncology and Molecular Radiation Sciences, Department of Medical Oncology, The Johns Hopkins University School of Medicine

Purpose: Androgen suppression (AS) combined with radiation therapy is currently a standard of care in the treatment of intermediate- and high-risk prostate cancer (PCa), and this combination compared with radiation alone has been shown to improve therapeutic outcomes. Historically, the optimal sequencing of the two modalities has not been thoroughly tested. It was recently discovered by our group that androgen stimulation of PCa cells can result in the formation of topoisomerase II beta (TOP2B)-mediated DNA double-strand breaks (DSBs). Here, aiming to exploit this finding, we investigated the extent and timing of TOP2B-mediated DSBs in vitro, as stimulated by androgens. In addition, we explored the combination of androgen stimulation with radiation and its effects on tumor growth in an animal model.

Methods: Androgen-sensitive LAPC4 PCa cells were grown in androgen-free media for 3 days. Androgen (R1881) was added at a final concentration of 100 nM, and the formation of DSBs at various time points was monitored by visualization of γH2AX foci and by comet assay analysis. For in vivo xenografts, nude mice were castrated, and silastic implants containing androgen were implanted. Cells were injected in the mouse flank. When tumor volumes reached approximately 0.1 cm3, the implants were removed for 16 days prior to reimplantation. A total of 8 Gy of ionizing radiation was delivered 4 days prior to reimplantation (traditional group) or at 12 hours after reimplantation (experimental group). The control group did not receive radiation; tumors were measured every other day, and time to 4× initial tumor volume was determined.

Results: Addition of androgen to LAPC4 cells resulted in a significant increase in the number of γH2AX foci per cell: untreated (11.6 ± 3.3), 2-hour treatment (19.3 ± 5.4), and 6-hour treatment (45.2 ± 8.1) (P < .01). Comet assay (tail moments) results were consistent with γH2AX findings: untreated (14.3 ± 6.4), 2-hour treatment (29.8 ± 7.4), and 6-hour treatment (39.4 ± 11.5) (P < .03). The time to 4× tumor growth was significantly delayed in the experimental group (63.0 d) compared with the traditional (31.5 d) and control groups (23.0 d) (P < .01).

Conclusions: We provide evidence that irradiating tumors at a time point when formation of androgen-induced DSBs is ongoing provides superior control when compared with radiation that is delivered when tumors are fully deprived of androgens. These results may have significant implications for altering current clinical management of intermediate-and high-risk prostate cancer treated with definitive radiotherapy. There are numerous approaches that could be utilized in leading to transient increases in testosterone in patients, along with AS cycling, that are currently being tested in animal models and being proposed for human trials. In light of the new details uncovered about the mechanisms of androgen receptor (AR) signaling and downstream affects at the level of DNA processing, taking advantage of the very mechanism by which prostate cancers may grow (AR pathway) and using this knowledge to further improve therapeutic ratios in the setting of definitive radiotherapy is an attractive approach.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Recent Videos
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Related Content